Skye Bioscience, Inc. SKYE 深 沪
等待开盘 09-26 09:30:00 美东时间
3.60
+0.020
+0.56%
华盛通- 最 高3.61
- 今 开3.56
- 成交量 28.90万股
- 最 低 3.36
- 昨 收 3.58
- 总市值 1.12亿
- 52周最高 5.96
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.14
- 委 比 0.31%
- 总股本 3098.84万
- 历史最高 17.6473
- 量 比 0.82
- 振 幅 6.98%
- 历史最低 1.14
- 每 手 1
- 风险率 3.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Could This New Drug Be The Safer Way To Fight Obesity?
Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.
09-20 02:19
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
Skye Bioscience announced Phase 1b results for nimacimab, showing safety, tolerability, and no neuropsychiatric adverse events in metabolic-associated steatotic liver disease (MASLD) patients. Gastrointestinal side effects were mild, supporting its potential in treating metabolic diseases. Key findings include predictable pharmacokinetics, low immunogenicity, and no serious adverse events or discontinuations. Nimacimab's differentiated tolerabili...
09-19 11:00
Skye's Nimacimab Boosts Tirzepatide Results And Helps Maintain Weight Loss In Mouse Studies
Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today reported results from two new
09-04 19:10
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
Skye Bioscience reported promising preclinical data for nimacimab, a peripheral CB1-inhibiting antibody, showing over 40% weight loss when combined with tirzepatide, superior post-treatment weight maintenance vs monlunabant, and reduced rebound weight gain. Nimacimab is positioned as a potential standalone, combination, and maintenance therapy for obesity, with Phase 2 results expected in late 2025.
09-04 11:00
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
Skye Bioscience has completed the 26-week primary endpoint of its Phase 2a CBeyond™ trial evaluating nimacimab, a peripheral CB1 inhibitor antibody, for obesity and overweight. The trial also includes a 26-week extension to assess 52-week data with a 13-week follow-up. Key points: nimacimab's potential as a monotherapy or in combination with semaglutide; focus on addressing limitations of GLP-1 drugs; and plans to report data from the extension i...
09-02 11:00
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
Skye Bioscience will host a virtual KOL event on September 4, 2025, at 8:00 AM ET, discussing upcoming Phase 2a CBeyond trial results of nimacimab, a peripheral CB1 antibody for obesity. The event, featuring key opinion leaders, will cover study success criteria, mechanism insights, new preclinical data, and a Q&A session. Registration is required for participation.
08-27 11:00
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
Skye Bioscience将参与多个投资和医疗会议，包括Cantor Global Healthcare Conference、H.C. Wainwright Global Investment Conference、Morgan Stanley Global Healthcare Conference及Obesity Science & Innovation和EASD会议，重点讨论肥胖治疗和代谢疾病。公司专注于开发基于G蛋白偶联受体的创新疗法，正在开展IIa期临床试验评估其药物nimacimab的安全性和疗效。如需更多信息，请访问公司官网。
08-21 11:00
美股大行评级 | Macquarie维持小鹏汽车"跑赢大市"评级，目标价升至25美元
今日重点评级关注：HC Wainwright & Co.：维持BioXcel Therapeutics"买入"评级，目标价从8美元升至10美元；Craig-Hallum：维持Fennec Pharmaceuticals"买入"评级，目标价从13美元升至14美元
08-18 10:22
Evercore ISI Group Initiates Coverage On Skye Bioscience with Outperform Rating, Announces Price Target of $10
Evercore ISI Group analyst Michael DiFiore initiates coverage on Skye Bioscience (NASDAQ:SKYE) with a Outperform rating and announces Price Target of $10.
08-16 01:52
Skye initiated at overweight at Evercore on obesity asset nimacimab
Evercore ISI is bullish on the prospects for Skye Bioscience (NASDAQ:SKYE) due to its development of the CB1 inhibitor nimacimab for obesity. The firm has a $10 price target (~206% upside based on Thu...
08-15 21:43
